CoChat

The DOI matches its Crossref record; 245 of the 245 references it cites were found in a registry or an index.

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease

Open access
Du, Haiyang, Meng, Xiaoyu, Yao, Yu, Xu, Jun · 2022 · Frontiers in Endocrinology

Abstract

Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer’s disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs used to treat T2DM have been gradually found to reduce the progression of AD in AD models. Of these drugs, glucagon-like peptide 1 receptor (GLP-1R) agonists are more effective and have fewer side effects. GLP-1R agonists have reducing neuroinflammation and oxidative stress, neurotrophic effects, decreasing Aβ deposition and tau hyperphosphorylation in AD models, which may be a potential drug for the treatment of AD. However, this needs to be verified by further clinical trials. This study aims to summarize the current information on the mechanisms and effects of GLP-1R agonists in AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2022.1033479

Cites

245 of 245 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Pathogenesis of AD and neuroprotective effects of GLP-1R agonists.
Figure 1 Pathogenesis of AD and neuroprotective effects of GLP-1R agonists.CC BY · PubMed Central
Figure 2 The amino acid structure of various GLP-1R agonists.
Figure 2 The amino acid structure of various GLP-1R agonists.CC BY · PubMed Central
Figure 3 Signaling pathways for GLP-1R agonists in regulating cellular events in AD.
Figure 3 Signaling pathways for GLP-1R agonists in regulating cellular events in AD.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 245 references

Cited by

See all 148

Metadata

Authors
Du, H., Meng, X., Yao, Y., & Xu, J.
Affiliations
  • Harbin Medical University (CN)
  • Tongji Hospital (CN)
Corresponding author
Xu, Jun
Venue
Frontiers in Endocrinology
Published
2022-11-17
Volume
13
Pages
1033479-1033479
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4309614066
Cited by
125
References
245
Citations by year
2026: 28 · 2025: 54 · 2024: 33 · 2023: 10
FWCI
3.34
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Ministry of Education of the People's Republic of China
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
Alzheimer's disease, GLP-1 receptor agonists, glucagon-like peptide-1, type 2 diabetes, insulin resistance, neuroinflammation, oxidative stress, neurotrophic effects, amyloid-beta deposition, tau hyperphosphorylation, drug repurposing
MeSH terms
Glucagon-Like Peptide-1 Receptor, Alzheimer Disease, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease. https://app.cochat.ai/papers/10.3389/fendo.2022.1033479
The paper
Du, H., Meng, X., Yao, Y., & Xu, J. (2022). The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2022.1033479

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.